InvestSMART

Next Science Limited (ASX:NXS)

ALERT: Price-sensitive ASX Announcement for NXS
Current share price for NXS : $0.145 -0.005 (-3.33%)+
Announcement
Release
30 Oct 2025 8:18AM
Price at Release
$0.150
Full Release
download
Summary
Next Science Limited, a medical technology company focused on reducing biofilm-based infections, reported its quarterly activity and cash flow for the period ending 30 September 2025. The company achieved a 3% increase in third-quarter product sales compared to the previous year, amounting to US$4.8 million, largely due to the performance of XPERIENCE and partner sales, despite a decline in DME sales. They reported direct product sales of US$2.5 million, which was a decrease of 28% from the previous year, accounting for 53% of total product sales. After completing the sale of substantial assets to OSARTIS GmbH for US$50 million, the company plans to return approximately US$30 million net proceeds to shareholders after deducting debts, transaction costs, and other liabilities. The company's cash receipts were US$6.5 million, reflecting a 59% increase year-on-year, with a closing cash balance of US$39.6 million and no debt following the repayment of a loan from Thorney Investment Group.
Key Points
  • 3rd Quarter FY25 product sales of US$4.8 million, up 3% from prior period.
  • Direct product sales decreased by 28% to US$2.5 million.
  • Sale of assets to OSARTIS GmbH for US$50 million completed.
  • Estimated net proceeds of US$30 million to be returned to shareholders.
  • Cash receipts increased by 59% to US$6.5 million.
  • Closing cash balance was US$39.6 million with no debt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.